Expansion of Indication in M-TEER: Is Moderate Mitral Regurgitation the New Target?

<p>Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: </p><ul><li>Grant Support/Research Contract - Abbott Vascular</li><li>Consultant Fee/Honoraria/Speaker’s Bureau - Edwards Lifesciences; Abbott</li></ul>